Cingulate Inc

CING

Company Profile

  • Business description

    Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

  • Contact

    1901 West 47th Place
    KansasKS66205
    USA

    T: +1 913 942-2300

    https://www.cingulate.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    14

Stocks News & Analysis

stocks

Reassuring organic growth for undervalued ASX share

Efficiency gains are starting to make their mark.
stocks

Big IPOs are enticing but are they good investments?

Historically, buzzy debuts have been painful for buyers.
stocks

This defensive ASX listed REIT offers a 5% yield

Solid outlook underpinned by rent uplifts and development pipeline.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,692.80143.80-1.63%
CAC 407,927.75152.99-1.89%
DAX 4024,802.78661.03-2.60%
Dow JONES (US)48,180.15916.91-1.87%
FTSE 10010,346.34106.34-1.02%
HKSE22,410.80430.82-1.89%
NASDAQ22,646.681,232.52-5.16%
Nikkei 22556,436.653,007.56-5.06%
NZX 50 Index14,107.41139.84-0.98%
S&P 5006,919.09256.74-3.58%
S&P/ASX 2008,592.60137.80-1.58%
SSE Composite Index3,533.7943.82-1.22%

Market Movers